We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.
The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".
Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.
Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.
& Survival analysisi
Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.
PTN is not prognostic in Glioblastoma Multiforme (TCGA)
Stage:
Survival analysis
Current cut offi
Current cut-off shows the cut-off (FPKM) currently selected. It may be changed manually. When the current cut-off is changed, the vertical dashed line indicating cut-off, the interactive survival scatter plot and the Kaplan-Meier curve will be automatically adjusted to show results accordingly.
:
Best expression cut offi
Based on the FPKM value of each gene, patients were classified into two groups and association between prognosis (survival) and gene expression (FPKM) was examined. The best expression cut-off refers the FPKM value that yields maximal difference with regard to survival between the two groups at the lowest log-rank P-value. Best expression cut-off was selected based on survival analysis .
When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the best expression cut-off.
Median expression refers to the median FPKM value calculated based on the gene expression (FPKM) data from all patients in this dataset. When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the median expression.
Median follow up time refers to the median time (years) after diagnosis with this type of cancer, based on clinical data from all patients in this dataset.
: 0.98
P scorei
Log-rank P value for Kaplan-Meier plot showing results from analysis of correlation between mRNA expression level and patient survival.
0.34
3-year survival highi
5-year survival for patients with higher expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
13%
3-year survival lowi
5-year survival for patients with lower expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
8%
TCGA RNA samplesi
RNA-seq data is reported as average FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA) .
Normal distribution across the dataset is visualized with box plots, shown as median and 25th and 75th percentiles. Points are displayed as outliers if they are above or below 1.5 times the interquartile range. FPKM values of the individual samples are presented next to the box plot.
Average TPM
849.3
Number of samples
141
Samples
Sample
Description
TPM
TCGA-28-5204-01A
72 years, male, white, stage:'--, dead, 454 days
3756.9
TCGA-19-2619-01A
55 years, female, black or african american, stage:'--, alive, 294 days
3334.8
TCGA-12-5299-01A
56 years, female, white, stage:'--, dead, 98 days
2759.3
TCGA-28-5209-01A
66 years, female, white, stage:'--, alive, 442 days
2385.6
TCGA-14-0787-01A
69 years, male, asian, stage:'--, dead, 68 days
2307.7
TCGA-06-0125-01A
63 years, female, white, stage:'--, dead, 1448 days
2185.0
TCGA-26-5139-01A
65 years, female, white, stage:'--, alive, 48 days
2119.8
TCGA-76-4932-01A
50 years, female, white, stage:'--, dead, 1458 days
1983.8
TCGA-76-4927-01A
58 years, male, white, stage:'--, dead, 535 days
1926.3
TCGA-28-5208-01A
52 years, male, white, stage:'--, dead, 544 days
1894.1
TCGA-27-2523-01A
63 years, male, white, stage:'--, dead, 489 days
1774.8
TCGA-06-5414-01A
61 years, male, white, stage:'--, alive, 273 days
1687.7
TCGA-06-2563-01A
72 years, female, white, stage:'--, alive, 932 days
1588.3
TCGA-27-1837-01A
36 years, male, white, stage:'--, dead, 427 days
1498.1
TCGA-12-0821-01A
62 years, male, white, stage:'--, dead, 323 days
1494.8
TCGA-41-2572-01A
67 years, male, white, stage:'--, dead, 406 days
1473.1
TCGA-14-1825-01A
70 years, male, white, stage:'--, dead, 232 days
1465.9
TCGA-06-5408-01A
54 years, female, white, stage:'--, dead, 357 days
1454.4
TCGA-06-2562-01A
81 years, male, white, stage:'--, dead, 382 days
1429.3
TCGA-27-1835-01A
53 years, female, white, stage:'--, dead, 648 days
1377.1
TCGA-15-0742-01A
65 years, male, white, stage:'--, dead, 419 days
1373.0
TCGA-06-0747-01A
53 years, male, white, stage:'--, dead, 82 days
1367.5
TCGA-27-2526-01A
79 years, female, white, stage:'--, dead, 87 days
1357.1
TCGA-12-3653-01A
34 years, female, white, stage:'--, dead, 442 days
1346.8
TCGA-06-0878-01A
74 years, male, white, stage:'--, alive, 218 days
1311.4
TCGA-06-2564-01A
50 years, male, white, stage:'--, alive, 181 days
1304.7
TCGA-06-2565-01A
59 years, male, asian, stage:'--, dead, 506 days
1294.3
TCGA-19-1390-01A
63 years, female, white, stage:'--, dead, 772 days
1292.0
TCGA-12-5295-01A
60 years, female, white, stage:'--, dead, 454 days
1276.7
TCGA-06-0211-01A
47 years, male, white, stage:'--, dead, 360 days
1263.2
TCGA-27-2524-01A
56 years, male, white, stage:'--, dead, 231 days
1221.5
TCGA-19-4065-01A
36 years, male, white, stage:'--, alive, 214 days
1210.7
TCGA-06-5418-01A
75 years, female, white, stage:'--, dead, 83 days
1179.4
TCGA-32-2638-01A
67 years, male, white, stage:'--, dead, 766 days
1173.7
TCGA-28-5207-01A
71 years, male, white, stage:'--, dead, 343 days
1170.1
TCGA-32-2634-01A
82 years, male, white, stage:'--, alive, 693 days
1157.1
TCGA-14-0789-01A
54 years, male, white, stage:'--, dead, 342 days
1132.2
TCGA-76-4931-01A
70 years, female, white, stage:'--, dead, 279 days
1114.5
TCGA-19-5960-01A
56 years, male, white, stage:'--, dead, 455 days
1112.6
TCGA-06-0184-01A
63 years, male, white, stage:'--, dead, 2126 days
1094.1
TCGA-27-2528-01A
62 years, male, white, stage:'--, dead, 480 days
1055.3
TCGA-32-1970-01A
59 years, male, white, stage:'--, dead, 468 days
1051.5
TCGA-14-1034-01A
60 years, female, stage:'--, dead, 485 days
1040.0
TCGA-06-2558-01A
75 years, female, white, stage:'--, dead, 380 days
1009.1
TCGA-06-0187-01A
69 years, male, white, stage:'--, dead, 828 days
976.5
TCGA-28-2509-01A
77 years, female, white, stage:'--, alive, 145 days
960.9
TCGA-26-5132-01A
74 years, male, white, stage:'--, alive, 286 days
928.5
TCGA-28-1753-01A
53 years, male, white, stage:'--, alive, 37 days
919.7
TCGA-12-0618-01A
49 years, male, white, stage:'--, dead, 395 days
915.5
TCGA-76-4925-01A
76 years, male, white, stage:'--, dead, 146 days
910.1
TCGA-06-0646-01A
60 years, male, white, stage:'--, dead, 175 days
908.2
TCGA-06-0210-01A
72 years, female, white, stage:'--, dead, 225 days
893.5
TCGA-06-0686-01A
53 years, male, white, stage:'--, dead, 432 days
891.8
TCGA-06-5412-01A
78 years, female, white, stage:'--, dead, 138 days
890.2
TCGA-32-5222-01A
66 years, male, white, stage:'--, dead, 585 days
885.0
TCGA-19-2624-01A
51 years, male, white, stage:'--, dead, 5 days
875.0
TCGA-06-0745-01A
59 years, male, white, stage:'--, dead, 239 days
861.9
TCGA-28-2514-01A
45 years, male, asian, stage:'--, alive, 160 days
851.2
TCGA-27-1831-01A
66 years, male, white, stage:'--, dead, 505 days
822.5
TCGA-12-3652-01A
60 years, male, white, stage:'--, dead, 1062 days
818.6
TCGA-06-0190-01A
62 years, male, white, stage:'--, dead, 317 days
787.5
TCGA-26-5133-01A
59 years, male, white, stage:'--, alive, 452 days
782.5
TCGA-12-0616-01A
36 years, female, white, stage:'--, dead, 448 days
772.6
TCGA-12-3650-01A
46 years, male, white, stage:'--, dead, 333 days
770.7
TCGA-28-2513-01A
69 years, female, white, stage:'--, alive, 222 days
740.6
TCGA-06-0644-01A
71 years, male, black or african american, stage:'--, dead, 384 days
736.6
TCGA-06-2570-01A
21 years, female, white, stage:'--, alive, 958 days
733.4
TCGA-06-2569-01A
24 years, female, black or african american, stage:'--, alive, 13 days
718.7
TCGA-41-5651-01A
59 years, female, black or african american, stage:'--, dead, 460 days
711.8
TCGA-06-0174-01A
54 years, male, white, stage:'--, dead, 98 days
686.6
TCGA-19-2620-01A
70 years, male, white, stage:'--, dead, 148 days
658.5
TCGA-06-0744-01A
66 years, male, white, stage:'--, dead, 1426 days
648.8
TCGA-26-5135-01A
72 years, female, white, stage:'--, dead, 270 days
646.7
TCGA-06-0157-01A
63 years, female, white, stage:'--, dead, 97 days
636.4
TCGA-06-0750-01A
43 years, male, white, stage:'--, dead, 28 days
632.6
TCGA-28-5216-01A
52 years, male, white, stage:'--, alive, 415 days
628.6
TCGA-32-2632-01A
80 years, male, white, stage:'--, dead, 269 days
620.6
TCGA-32-1982-01A
76 years, female, white, stage:'--, dead, 142 days
613.8
TCGA-14-2554-01A
52 years, female, white, stage:'--, dead, 532 days
609.6
TCGA-28-5215-01A
62 years, female, white, stage:'--, dead, 335 days
606.3
TCGA-06-2561-01A
53 years, female, white, stage:'--, dead, 537 days
594.3
TCGA-32-1980-01A
72 years, male, white, stage:'--, dead, 36 days
589.9
TCGA-32-2615-01A
62 years, male, white, stage:'--, dead, 485 days
589.8
TCGA-06-0158-01A
73 years, male, white, stage:'--, dead, 329 days
589.6
TCGA-06-0238-01A
46 years, male, white, stage:'--, dead, 405 days
575.1
TCGA-06-5413-01A
67 years, male, white, stage:'--, alive, 268 days
570.3
TCGA-06-5410-01A
72 years, female, white, stage:'--, dead, 108 days
560.3
TCGA-06-0882-01A
30 years, male, white, stage:'--, dead, 632 days
555.3
TCGA-27-2521-01A
34 years, male, white, stage:'--, dead, 510 days
551.4
TCGA-27-2519-01A
48 years, male, white, stage:'--, dead, 550 days
546.2
TCGA-06-5416-01A
23 years, female, white, stage:'--, alive, 204 days
526.3
TCGA-06-5856-01A
58 years, male, white, stage:'--, dead, 114 days
510.6
TCGA-02-2483-01A
43 years, male, asian, stage:'--, alive, 466 days
508.6
TCGA-32-2616-01A
48 years, female, white, stage:'--, dead, 224 days
504.3
TCGA-27-1830-01A
57 years, male, white, stage:'--, dead, 154 days
500.8
TCGA-06-5411-01A
51 years, male, white, stage:'--, dead, 254 days
480.6
TCGA-06-5858-01A
45 years, female, white, stage:'--, alive, 187 days
475.4
TCGA-14-1829-01A
57 years, male, black or african american, stage:'--, alive, 218 days
471.6
TCGA-06-2559-01A
83 years, male, white, stage:'--, dead, 150 days
465.4
TCGA-02-2485-01A
53 years, male, black or african american, stage:'--, alive, 470 days
464.4
TCGA-27-1834-01A
56 years, male, white, stage:'--, dead, 1233 days
463.1
TCGA-76-4929-01A
76 years, female, white, stage:'--, dead, 111 days
449.4
TCGA-28-5220-01A
67 years, male, white, stage:'--, dead, 388 days
446.9
TCGA-06-0138-01A
43 years, male, white, stage:'--, dead, 737 days
427.6
TCGA-12-0619-01A
60 years, male, white, stage:'--, dead, 1062 days
420.2
TCGA-06-0168-01A
59 years, female, white, stage:'--, dead, 598 days
417.8
TCGA-06-0156-01A
57 years, male, white, stage:'--, dead, 178 days
415.5
TCGA-27-1832-01A
59 years, female, white, stage:'--, dead, 300 days
409.7
TCGA-02-0047-01A
78 years, male, white, stage:'--, dead, 448 days
402.5
TCGA-19-2629-01A
60 years, male, white, stage:'--, dead, 737 days
393.3
TCGA-41-3915-01A
48 years, male, white, stage:'--, dead, 360 days
377.8
TCGA-06-0129-01A
30 years, male, asian, stage:'--, dead, 1024 days
368.8
TCGA-32-4213-01A
47 years, female, white, stage:'--, alive, 604 days
357.8
TCGA-06-0743-01A
69 years, male, white, stage:'--, dead, 803 days
357.3
TCGA-14-1823-01A
58 years, female, white, stage:'--, dead, 543 days
350.5
TCGA-16-0846-01A
85 years, male, white, stage:'--, dead, 119 days
347.3
TCGA-14-0817-01A
69 years, female, white, stage:'--, dead, 164 days
346.9
TCGA-26-5134-01A
74 years, male, white, stage:'--, alive, 167 days
327.4
TCGA-08-0386-01A
74 years, male, white, stage:'--, dead, 548 days
324.6
TCGA-06-0219-01A
67 years, male, white, stage:'--, dead, 22 days
323.1
TCGA-06-5859-01A
63 years, male, white, stage:'--, alive, 139 days
318.0
TCGA-06-0141-01A
62 years, male, white, stage:'--, dead, 313 days
297.2
TCGA-06-0749-01A
50 years, male, black or african american, stage:'--, dead, 82 days
285.7
TCGA-41-4097-01A
63 years, female, white, stage:'--, dead, 6 days
283.1
TCGA-06-0645-01A
55 years, female, white, stage:'--, dead, 175 days
282.0
TCGA-41-2571-01A
89 years, male, white, stage:'--, dead, 26 days
280.2
TCGA-14-0871-01A
74 years, female, white, stage:'--, dead, 880 days
275.5
TCGA-06-5417-01A
45 years, female, white, stage:'--, alive, 155 days
272.1
TCGA-26-1442-01A
43 years, male, white, stage:'--, alive, 953 days
222.5
TCGA-06-1804-01A
81 years, female, white, stage:'--, dead, 414 days
220.5
TCGA-15-1444-01A
21 years, male, white, stage:'--, dead, 1537 days
216.9
TCGA-06-2567-01A
65 years, male, white, stage:'--, dead, 133 days
201.0
TCGA-06-2557-01A
76 years, male, black or african american, stage:'--, dead, 33 days
189.0
TCGA-02-2486-01A
64 years, male, white, stage:'--, dead, 618 days
188.1
TCGA-19-2625-01A
76 years, female, white, stage:'--, dead, 124 days
The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.
The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".
Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.
Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.
& Survival analysisi
Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.
PTN is not prognostic in Glioblastoma Multiforme (validation)
Stage:
Survival analysis
Current cut offi
Current cut-off shows the cut-off (FPKM) currently selected. It may be changed manually. When the current cut-off is changed, the vertical dashed line indicating cut-off, the interactive survival scatter plot and the Kaplan-Meier curve will be automatically adjusted to show results accordingly.
:
Best expression cut offi
Based on the FPKM value of each gene, patients were classified into two groups and association between prognosis (survival) and gene expression (FPKM) was examined. The best expression cut-off refers the FPKM value that yields maximal difference with regard to survival between the two groups at the lowest log-rank P-value. Best expression cut-off was selected based on survival analysis .
When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the best expression cut-off.
Median expression refers to the median FPKM value calculated based on the gene expression (FPKM) data from all patients in this dataset. When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the median expression.
Median follow up time refers to the median time (years) after diagnosis with this type of cancer, based on clinical data from all patients in this dataset.
: 0.99
P scorei
Log-rank P value for Kaplan-Meier plot showing results from analysis of correlation between mRNA expression level and patient survival.
0.0026
3-year survival highi
5-year survival for patients with higher expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
0%
3-year survival lowi
5-year survival for patients with lower expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
46%
TCGA RNA samplesi
RNA-seq data is reported as average FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA) .
Normal distribution across the dataset is visualized with box plots, shown as median and 25th and 75th percentiles. Points are displayed as outliers if they are above or below 1.5 times the interquartile range. FPKM values of the individual samples are presented next to the box plot.
Average TPM
304.4
Number of samples
58
Samples
Sample
Description
TPM
AK035
N, NA, stage:NA, dead, 210 days
1078.7
AK142
N, NA, stage:NA, alive, 90 days
838.1
AK123
N, NA, stage:NA, dead, 180 days
777.6
AK139
N, NA, stage:NA, dead, 270 days
763.9
AK099
N, NA, stage:NA, dead, 420 days
739.5
AK081
N, NA, stage:NA, dead, 180 days
607.0
AK227
N, NA, stage:NA, alive, 300 days
600.5
AK089
N, NA, stage:NA, dead, 330 days
546.6
AK088
N, NA, stage:NA, dead, 360 days
508.2
AK053
N, NA, stage:NA, dead, 300 days
504.1
AK165
N, NA, stage:NA, alive, 360 days
502.4
AK071
N, NA, stage:NA, dead, 540 days
472.0
AK173
N, NA, stage:NA, dead, 180 days
459.0
AK226
N, NA, stage:NA, dead, 360 days
451.5
AK079
N, NA, stage:NA, dead, 210 days
448.9
AK178
N, NA, stage:NA, dead, 240 days
448.6
AK049
N, NA, stage:NA, dead, 180 days
367.7
AK074
N, NA, stage:NA, alive, 300 days
337.7
AK149
N, NA, stage:NA, dead, 420 days
325.5
AK156
N, NA, stage:NA, dead, 330 days
309.7
AK100
N, NA, stage:NA, alive, 960 days
295.8
AK002
N, NA, stage:NA, dead, 570 days
290.9
AK195
N, NA, stage:NA, dead, 390 days
279.6
AK133
N, NA, stage:NA, dead, 360 days
269.5
AK072
N, NA, stage:NA, dead, 150 days
266.4
AK051
N, NA, stage:NA, dead, 360 days
258.4
AK205
N, NA, stage:NA, dead, 120 days
255.6
AK124
N, NA, stage:NA, alive, 1920 days
252.0
AK158
N, NA, stage:NA, dead, 360 days
248.7
AK117
N, NA, stage:NA, dead, 210 days
248.7
AK134
N, NA, stage:NA, dead, 360 days
242.7
AK098
N, NA, stage:NA, dead, 660 days
239.3
AK043
N, NA, stage:NA, alive, 660 days
238.9
AK091
N, NA, stage:NA, dead, 210 days
238.2
AK003
N, NA, stage:NA, dead, 600 days
220.1
AK188
N, NA, stage:NA, alive, 420 days
205.8
AK236
N, NA, stage:NA, dead, 360 days
178.3
AK183
N, NA, stage:NA, alive, 360 days
171.7
AK218
N, NA, stage:NA, dead, 180 days
168.7
AK199
N, NA, stage:NA, alive, 1860 days
168.2
AK216
N, NA, stage:NA, dead, 360 days
147.4
AK213
N, NA, stage:NA, alive, 2010 days
146.5
AK103
N, NA, stage:NA, alive, 1320 days
144.9
AK076
N, NA, stage:NA, alive, 660 days
132.1
AK068
N, NA, stage:NA, alive, 360 days
129.2
AK231
N, NA, stage:NA, dead, 240 days
122.7
AK006
N, NA, stage:NA, dead, 360 days
117.7
AK041
N, NA, stage:NA, alive, 810 days
101.4
AK030
N, NA, stage:NA, dead, 120 days
95.5
AK153
N, NA, stage:NA, dead, 240 days
90.5
AK005
N, NA, stage:NA, dead, 240 days
87.0
AK085
N, NA, stage:NA, alive, 660 days
84.7
AK102
N, NA, stage:NA, alive, 1740 days
81.0
AK185
N, NA, stage:NA, alive, 330 days
79.6
AK055
N, NA, stage:NA, dead, 240 days
77.4
AK015
N, NA, stage:NA, alive, 720 days
70.5
AK066
N, NA, stage:NA, alive, 960 days
70.2
AK167
N, NA, stage:NA, dead, 180 days
54.3
Show allShow less
GLIOBLASTOMA MULTIFORME - Protein relative expression (CPTAC)
Number of samples
110
Samples
Sample ID
Sample type
nRPX
CPT0182580003
Tumor
2.8
CPT0208980003
Tumor
1.8
CPT0217000004
Tumor
1.3
CPT0205670004
Tumor
1.0
CPT0168830003
Tumor
0.9
CPT0224390004
Tumor
0.9
CPT0123530003
Tumor
0.8
CPT0093510003
Tumor
0.8
CPT0217100003
Tumor
0.7
CPT0206880003
Tumor
0.7
CPT0225730003
Tumor
0.7
CPT0162100003
Tumor
0.7
CPT0189750004
Tumor
0.7
CPT0093450003
Tumor
0.7
CPT0079790003
Tumor
0.6
CPT0171580008
Tumor
0.6
CPT0167860004
Tumor
0.6
CPT0167530003
Tumor
0.4
CPT0190360004
Tumor
0.4
CPT0217880003
Tumor
0.4
CPT0189570004
Tumor
0.4
CPT0218960004
Tumor
0.4
CPT0207090003
Tumor
0.4
CPT0206330003
Tumor
0.3
CPT0205450004
Tumor
0.3
CPT0168380003
Tumor
0.3
CPT0206000004
Tumor
0.3
CPT0167750004
Tumor
0.2
CPT0189850004
Tumor
0.2
CPT0078580003
Tumor
0.2
CPT0225760003
Tumor
0.1
CPT0125510003
Tumor
0.1
CPT0104330003
Tumor
0.1
CPT0209440003
Tumor
0.1
CPT0205890003
Tumor
0.0
CPT0167640003
Tumor
0.0
CPT0093360003
Tumor
0.0
CPT0087680003
Tumor
-0.1
CPT0224330003
Tumor
-0.1
CPT0168590003
Tumor
-0.1
CPT0218830004
Tumor
-0.1
CPT0207030003
Tumor
-0.1
CPT0228220003
Tumor
-0.1
CPT0093590003
Tumor
-0.1
CPT0167970003
Tumor
-0.2
CPT0087570003
Tumor
-0.2
CPT0168270003
Tumor
-0.2
CPT0168080003
Tumor
-0.2
CPT0218690004
Tumor
-0.3
CPT0089150003
Tumor
-0.3
CPT0189250003
Tumor
-0.3
CPT0206780003
Tumor
-0.3
CPT0168720003
Tumor
-0.3
CPT0064890003
Tumor
-0.3
CPT0205570003
Tumor
-0.3
CPT0204360003
Normal
-0.3
CPT0189460003
Tumor
-0.4
CPT0175060003
Tumor
-0.4
CPT0182500003
Tumor
-0.4
CPT0218890004
Tumor
-0.5
CPT0087950003
Tumor
-0.5
CPT0204420003
Normal
-0.6
CPT0218670003
Tumor
-0.6
CPT0217060003
Tumor
-0.6
CPT0224600003
Tumor
-0.6
CPT0218330004
Tumor
-0.6
CPT0204340003
Normal
-0.6
CPT0217710008
Tumor
-0.6
CPT0071100003
Tumor
-0.7
CPT0162020003
Tumor
-0.7
CPT0206450003
Tumor
-0.7
CPT0204410003
Normal
-0.7
CPT0219080004
Tumor
-0.7
CPT0204400003
Normal
-0.7
CPT0196850003
Tumor
-0.8
CPT0204330003
Normal
-0.9
CPT0217190003
Tumor
-0.9
CPT0162140003
Tumor
-0.9
CPT0093550003
Tumor
-0.9
CPT0125220003
Tumor
-0.9
CPT0127420003
Tumor
-0.9
CPT0204370003
Normal
-0.9
CPT0221180003
Tumor
-0.9
CPT0190240004
Tumor
-1.0
CPT0127480003
Tumor
-1.0
CPT0092440003
Tumor
-1.0
CPT0199770003
Tumor
-1.0
CPT0182550003
Tumor
-1.0
CPT0205780003
Tumor
-1.0
CPT0161730003
Tumor
-1.0
CPT0201710003
Tumor
-1.1
CPT0186100003
Tumor
-1.1
CPT0206110003
Tumor
-1.2
CPT0216920008
Tumor
-1.2
CPT0204390003
Normal
-1.2
CPT0217430008
Tumor
-1.4
CPT0206560003
Tumor
-1.4
CPT0218770003
Tumor
-1.4
CPT0125570003
Tumor
-1.4
CPT0204380003
Normal
-1.4
CPT0206230003
Tumor
-1.5
CPT0189650004
Tumor
-1.9
CPT0168480003
Tumor
-1.9
CPT0204350003
Normal
-1.9
CPT0104220003
Tumor
-2.0
CPT0064650003
Tumor
-2.1
CPT0002410011
Tumor
-2.1
CPT0087730003
Tumor
-2.2
CPT0206670004
Tumor
-2.4
CPT0224540004
Tumor
-2.5
Show allShow less
GLIOMA - Protein expressioni
A mouse-over function shows sample information and annotation data. Click on an image to view it in a full screen mode. Samples can be filtered based on level of antibody staining by selecting one or several of the following categories: high, medium, low and not detected. The assay and annotation is described here.
Note that samples used for immunohistochemistry by the Human Protein Atlas do not correspond to samples in the TCGA dataset.
Antibody stainingi
Antibody staining in the annotated cell types in the current human tissue is reported as not detected, low, medium, or high, based on conventional immunohistochemistry profiling in selected tissues. This score is based on the combination of the staining intensity and fraction of stained cells.
Each image is clickable and will lead to virtual microscopy that enables deeper exploration of all samples and also displays staining intensity scores, fraction scores and subcellular localization as well as patient and tissue information for each sample.